Laboratory Corporation of America Holdings with ticker code (LH) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 295 and 201.88 calculating the average target price we see $268.61. Given that the stocks previous close was at $207.32 this now indicates there is a potential upside of 29.6%. The 50 day moving average now sits at $193.04 and the 200 day moving average is $197.58. The market cap for the company is 18.51B. The stock price is currently at: 208.92 USD
The potential market cap would be $23,982,513,755 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.67, revenue per share of 164.13 and a 5.43% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
